Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Vivos Therapeutics, Inc.
organization3 mentionslast seen Oct 21, 2026
Medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea and other breathing and sleep disorders.
Relationships 18
- Vivos Therapeutics, Inc.employsRoman Franklin99% confidence3 sources
- Vivos Therapeutics, Inc.employsR. Kirk Huntsman99% confidence3 sources
- Vivos Therapeutics, Inc.acquiresSOD Sciences, Inc.97% confidence1 source
- Vivos Therapeutics, Inc.acquiresSOD Sciences, Inc.96% confidence1 source
- Vivos Therapeutics, Inc.acquirespseudohypoxia early-warning test96% confidence1 source
- Vivos Therapeutics, Inc.acquirespseudohypoxia early-warning test96% confidence1 source
- Vivos Therapeutics, Inc.developsobstructive sleep apnea treatment93% confidence1 source
- Vivos Therapeutics, Inc.conforms toNasdaq Listing Rule 5550(b)(1)93% confidence1 source
- Vivos Therapeutics, Inc.developsCARE oral appliances93% confidence1 source
- U.S. Food and Drug AdministrationapprovesVivos Therapeutics, Inc.92% confidence1 source
- Vivos Therapeutics, Inc.acquiresSOD Sciences, Inc.92% confidence1 source
- Vivos Therapeutics, Inc.acquirespseudohypoxia early-warning test90% confidence1 source
- Vivos Therapeutics, Inc.developsat-home oxygen desaturation and recovery testing90% confidence1 source
- The Nasdaq Stock Market LLCapprovesVivos Therapeutics, Inc.85% confidence1 source
- Vivos Therapeutics, Inc.suppliesAmerican Health Associates80% confidence1 source
- Vivos Therapeutics, Inc.suppliesCleveland Clinic Weston80% confidence1 source
- Streeterville Capital, LLCownsVivos Therapeutics, Inc.80% confidence1 source
- American Health AssociatessuppliesVivos Therapeutics, Inc.70% confidence1 source
Relationship
Vivos Therapeutics, Inc.employsR. Kirk Huntsman
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 21, 2026Vivos Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
- filingSEC EDGAROct 19, 2026Vivos Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 3.02: Unregistered Sales of Equity Securities; Item 3.03: Material Modifications to Rights of Security Holders; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
- filingSEC EDGAROct 15, 2026Vivos Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Vivos Chairman and CEO R. Kirk Huntsman